Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2009

Open Access 01-06-2009 | Original Article

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

Authors: Corine Ekhart, Sjoerd Rodenhuis, Jan H. M. Schellens, Jos H. Beijnen, Alwin D. R. Huitema

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2009

Login to get access

Abstract

Purpose

The purpose of this study was to determine the potential utility of alternative weight descriptors in the Cockcroft–Gault equation to more accurately predict carboplatin clearance in underweight, normal weight, overweight and obese patients.

Methods

Clearance values obtained from individual fits using NONMEM were compared to predicted carboplatin clearances calculated using the modified Calvert formula in which creatinine clearance was calculated with the Cockcroft–Gault equation using diverse weight descriptors.

Results

This study indicated that lean body mass was the best weight descriptor in underweight and normal weight patients, while adjusted ideal body weight was the best weight descriptor in overweight and obese patients. However, a flat dose based on the population carboplatin clearance performed better in all weight categories than the use of the Cockcroft–Gault equation with diverse weight descriptors.

Conclusion

These results suggest that in overweight and obese patients, with a normal renal function, a flat carboplatin dose should be administered, based on the population carboplatin clearance (8.38 l/h = 140 mL/min). Thus, in case an AUC of 5 mg min/mL is desired, the appropriate dose for carboplatin would be 5 × 140 = 700 mg.
Literature
1.
van der Vijgh WJ (1991) Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21(4):242–261PubMedCrossRef
2.
Kloft C, Siegert W, Beyer J, Jaehde U (2002) Toxicity of high-dose carboplatin: ultrafiltered and not total plasma pharmacokinetics is of clinical relevance. J Clin Pharmacol 42(7):762–773PubMedCrossRef
3.
Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7(11):1748–1756PubMed
4.
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31–41PubMedCrossRef
5.
Ekhart C, de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH (2006) Flat dosing of carboplatin is justified in adult patients with normal renal function. Clin Cancer Res 12(21):6502–6508PubMedCrossRef
6.
Spinler SA, Nawarskas JJ, Boyce EG, Connors JE, Charland SL, Goldfarb S (1998) Predictive performance of ten equations for estimating creatinine clearance in cardiac patients Iohexol Cooperative Study Group. Ann Pharmacother 32(12):1275–1283PubMedCrossRef
7.
de Jonge ME, Mathot RA, van Dam SM, Beijnen JH, Rodenhuis S (2002) Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin. Cancer Chemother Pharmacol 50(3):251–255PubMedCrossRef
8.
Herrington JD, Tran HT, Riggs MW (2006) Prospective evaluation of carboplatin AUC dosing in patients with a BMI > or =27 or cachexia. Cancer Chemother Pharmacol 57(2):241–247PubMedCrossRef
9.
Salazar DE, Corcoran GB (1988) Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 84(6):1053–1060PubMedCrossRef
10.
De Jonge ME, Van den Bongard HJ, Huitema ADR, Mathot RA, Rosing H, Baas P et al (2004) Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. Clin Cancer Res 10(7):2237–2244PubMedCrossRef
11.
Huitema ADR, Spaander M, Mathot RAA, Tibben MM, Holtkamp MJ, Beijnen JH et al (2002) Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. Ann Oncol 13(3):374–384PubMedCrossRef
12.
Huizing MT, van Warmerdam LJ, Rosing H, Schaefers MC, Lai A, Helmerhorst TJ et al (1997) Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol 15(5):1953–1964PubMed
13.
Huizing MT, Giaccone G, van Warmerdam LJ, Rosing H, Bakker PJ, Vermorken JB et al (1997) Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol 15(1):317–329PubMed
14.
van Warmerdam LJC, Huizing MT, Giaccone G, Postmus PE, Bokkel Huinink WW, van Zandwijk N et al (1997) Clinical pharmacology of carboplatin administered in combination with paclitaxel. Semin Oncol 24(1 Suppl 2):S2PubMed
15.
Van Warmerdam LJC, Van Tellingen O, Maes RAA, Beijnen JH (1995) Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry. Fresenius J Anal Chem 351:777–781CrossRef
16.
Beal SL, Sheiner LB (2006) User’s Guides, NONMEM Project Group. University of California at San Francisco, San Francisco 2006. 1998
17.
18.
19.
Davis RL, Quenzer RW, Bozigian HP, Warner CW (1990) Pharmacokinetics of ranitidine in morbidly obese women. DICP 24(11):1040–1043PubMed
20.
Dionne RE, Bauer LA, Gibson GA, Griffen WO Jr, Blouin RA (1981) Estimating creatinine clearance in morbidity obese patients. Am J Hosp Pharm 38(6):841–844PubMed
21.
Stokholm KH, Brochner-Mortensen J, Hoilund-Carlsen PF (1980) Increased glomerular filtration rate and adrenocortical function in obese women. Int J Obes 4(1):57–63PubMed
22.
Ducharme MP, Slaughter RL, Edwards DJ (1994) Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 16(5):513–518PubMedCrossRef
23.
Allard S, Kinzig M, Boivin G, Sorgel F, LeBel M (1993) Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther 54(4):368–373PubMed
24.
Reiss RA, Haas CE, Karki SD, Gumbiner B, Welle SL, Carson SW (1994) Lithium pharmacokinetics in the obese. Clin Pharmacol Ther 55(4):392–398PubMed
25.
Bauer LA, Wareing-Tran C, Edwards WA, Raisys V, Ferreri L, Jack R et al (1985) Cimetidine clearance in the obese. Clin Pharmacol Ther 37(4):425–430PubMed
26.
Christoff PB, Conti DR, Naylor C, Jusko WJ (1983) Procainamide disposition in obesity. Drug Intell Clin Pharm 17(7–8):516–522PubMed
27.
Verhave JC, Fesler P, Ribstein J, Du CG, Mimran A (2005) Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis 46(2):233–241PubMedCrossRef
28.
van de Ree MA, Christiaan G, Huisman MV, van der Vijver JC, Meinders AE (2001) Monitoring renal function in obese patients with type 2 diabetes mellitus in daily practice. Diabetes Nutr Metab 14(2):66–70PubMed
29.
Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J et al (2007) Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 25(30):4707–4713PubMedCrossRef
30.
Benezet S, Guimbaud R, Chatelut E, Chevreau C, Bugat R, Canal P (1997) How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients. Ann Oncol 8(6):607–609PubMedCrossRef
31.
Kloft C, Siegert W, Jaehde U (2003) Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer. Br J Cancer 89(5):787–794PubMedCrossRef
Metadata
Title
Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Authors
Corine Ekhart
Sjoerd Rodenhuis
Jan H. M. Schellens
Jos H. Beijnen
Alwin D. R. Huitema
Publication date
01-06-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0856-x

Other articles of this Issue 1/2009

Cancer Chemotherapy and Pharmacology 1/2009 Go to the issue

Short Communication

Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report

Short Communication

Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?

Original Article

A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma

Clinical Trial Report

Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study

Short Communication

To widen the setting of cancer patients who could benefit from metronomic capecitabine

Original Article

Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits